Abstract
A monoclonal antibody (MAb) directed against doxorubicin (DXR), denominated MAD11, was found to exert an antidotal action by modulating the kinetic and dynamic characteristics of the drug. In vitro, MAD11 has been found to reduce the cytotoxicity of DXR and the drug uptake on spleen lymphocytes more efficiently than on tumor cells (P388 leukemia cells). In vivo, the anti-DXR MAb modified the drug distribution; the drug uptake was found to be reduced in the intestine and myocardial tissues and increased in the tumor, liver and spleen. In mice treated with DXR, the administration of anti-DXR MAb exerted an antidotal activity which was proved by the reduction in body-weight loss and mortality. In contrast, the therapeutic efficacy of the drug in P388-tumor-bearing mice was not influenced by the anti-DXR MAb.
| Original language | English |
|---|---|
| Pages (from-to) | 617-620 |
| Number of pages | 4 |
| Journal | International Journal of Cancer |
| Volume | 50 |
| Issue number | 4 |
| Publication status | Published - 1992 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
An anti-doxorubicin monoclonal antibody modulates kinetic and dynamic characteristics of the drug. / Sardini, A.; Villa, E.; Morelli, D.; Ghione, M.; Menard, S.; Colnaghi, M. I.; Balsari, A.
In: International Journal of Cancer, Vol. 50, No. 4, 1992, p. 617-620.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - An anti-doxorubicin monoclonal antibody modulates kinetic and dynamic characteristics of the drug
AU - Sardini, A.
AU - Villa, E.
AU - Morelli, D.
AU - Ghione, M.
AU - Menard, S.
AU - Colnaghi, M. I.
AU - Balsari, A.
PY - 1992
Y1 - 1992
N2 - A monoclonal antibody (MAb) directed against doxorubicin (DXR), denominated MAD11, was found to exert an antidotal action by modulating the kinetic and dynamic characteristics of the drug. In vitro, MAD11 has been found to reduce the cytotoxicity of DXR and the drug uptake on spleen lymphocytes more efficiently than on tumor cells (P388 leukemia cells). In vivo, the anti-DXR MAb modified the drug distribution; the drug uptake was found to be reduced in the intestine and myocardial tissues and increased in the tumor, liver and spleen. In mice treated with DXR, the administration of anti-DXR MAb exerted an antidotal activity which was proved by the reduction in body-weight loss and mortality. In contrast, the therapeutic efficacy of the drug in P388-tumor-bearing mice was not influenced by the anti-DXR MAb.
AB - A monoclonal antibody (MAb) directed against doxorubicin (DXR), denominated MAD11, was found to exert an antidotal action by modulating the kinetic and dynamic characteristics of the drug. In vitro, MAD11 has been found to reduce the cytotoxicity of DXR and the drug uptake on spleen lymphocytes more efficiently than on tumor cells (P388 leukemia cells). In vivo, the anti-DXR MAb modified the drug distribution; the drug uptake was found to be reduced in the intestine and myocardial tissues and increased in the tumor, liver and spleen. In mice treated with DXR, the administration of anti-DXR MAb exerted an antidotal activity which was proved by the reduction in body-weight loss and mortality. In contrast, the therapeutic efficacy of the drug in P388-tumor-bearing mice was not influenced by the anti-DXR MAb.
UR - http://www.scopus.com/inward/record.url?scp=0026539380&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026539380&partnerID=8YFLogxK
M3 - Article
C2 - 1537626
AN - SCOPUS:0026539380
VL - 50
SP - 617
EP - 620
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 4
ER -